- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00356720
Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma
July 25, 2006 updated by: Laboratoires Thea
Clinical Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% (Instilled Twice Daily for 2 or 3 Days) Versus Oral Azithromycin in Treatment of Trachoma
To assess in children the efficacy and safety of 2 dosing regimens of T1225 1.5% eye drops, in comparison to a reference product, single-dose oral azithromycin (AZM) 20 mg/kg, for the treatment of active trachoma.
Evaluation of clinical efficacy was primary (% of clinical cure at Day 60 in Per Protocol Set), microbiological evaluation was secondary
Study Overview
Detailed Description
The aim of the present study was to compare the efficacy of the dosing regimen which was demonstrated in pharmacokinetic studies to be the best candidate for trachoma treatment (T1225 1.5% eye drops BID for 3 days) with a shorter duration of treatment (T1225 1.5% eye drops BID for 2 days) and with a single oral administration of AZM (20 mg/kg) in patients suffering from active trachoma.
The study was to be performed in approximately 600 children (aged 1 to 10 years) from Guinea Conakry and Pakistan.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 10 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female aged 1-10 years;
- written informed consent by legally acceptable representative;
- TF+ TI0 (trachomatous inflammation - follicular) or TF+TI+ (trachomatous inflammation - follicular and intense) on simplified World Health Organisation (WHO) grading system
Exclusion Criteria:
- Trichiasis or corneal opacity;
- palpebral deformation;
- clinically significant ocular abnormality;
- ocular infection;
- organic amblyopia;
- hypersensitivity to treatments' components;
- immunosuppressive conditions;
- systemic AZM or steroids;
- topical ophthalmic antibiotics within 3 months;
- other systemic antibiotics within 1 month;
- topical (ocular, nasal, bronchial etc.) treatments within 1 week;
- systemic non-steroidal anti-inflammatory drugs on day before Day 0
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Cure at end of study, i.e. TF0 grade on simplified WHO trachoma grading system < 5 follicles ≥ 0.5 mm diameter in upper tarsal conjunctiva) in the worse eye
|
at the end of the study
|
Secondary Outcome Measures
Outcome Measure |
---|
Tolerance
|
Cure at Days 30 and 60,
|
cure in both eyes,
|
trachoma grades at each visit;
|
microbiological cure;
|
Ocular signs (bulbar conjunctival hyperaemia, discharge; lachrymation;
|
Global efficacy assessment by investigator.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Isabelle COCHEREAU, Professor, CHU d'Angers, France
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Study Completion
May 1, 2004
Study Registration Dates
First Submitted
July 25, 2006
First Submitted That Met QC Criteria
July 25, 2006
First Posted (Estimate)
July 26, 2006
Study Record Updates
Last Update Posted (Estimate)
July 26, 2006
Last Update Submitted That Met QC Criteria
July 25, 2006
Last Verified
July 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Eye Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Conjunctivitis
- Conjunctival Diseases
- Corneal Diseases
- Chlamydiaceae Infections
- Eye Infections, Bacterial
- Eye Infections
- Chlamydia Infections
- Conjunctivitis, Bacterial
- Trachoma
- Anti-Infective Agents
- Anti-Bacterial Agents
- Azithromycin
Other Study ID Numbers
- LT1225-PIII-10/03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trachoma
-
University of California, San FranciscoNational Eye Institute (NEI); Institut National de Recherche Biomédicale. Kinshasa...Not yet recruitingTrachomaCongo, The Democratic Republic of the
-
Emory UniversityThe Carter CenterSuspended
-
University of California, San FranciscoCompleted
-
Johns Hopkins UniversityBill and Melinda Gates FoundationCompleted
-
University of California, San FranciscoNational Eye Institute (NEI); Programme National de Santé Oculaire (PNSO)Recruiting
-
University of California, San FranciscoNational Eye Institute (NEI); Emory University; The Carter Center; Amhara Public...Recruiting
-
London School of Hygiene and Tropical MedicineUniversity College London Hospitals; World Health Organization; RTI International and other collaboratorsTerminated
-
London School of Hygiene and Tropical MedicineFederal Minstry of Health of Ethiopia; Oromia Regional Health Bureau, Ethiopia and other collaboratorsCompletedTrachomaUnited Kingdom, Ethiopia
-
Johns Hopkins UniversityNational Eye Institute (NEI)Completed
-
Johns Hopkins UniversityWellcome TrustCompletedTrachomaUnited States
Clinical Trials on Azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
PfizerCompletedBacterial Infections
-
Sheba Medical CenterUnknown
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States